Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06380517 · Jaeb Center for Health Research

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

(ATS23)

What this study is about

In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.

View original scientific description

In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.

Interventions

DEVICE

Luminopia

dichoptic movies/shows shown through a virtual reality headset

OTHER

Eye Patch

Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye

Primary outcome measures

Change in amblyopic eye logMAR distance VA between randomization and 26 weeks

Time frame: 26 Weeks

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • to be eligible to participate in the study.
  • Age 4 to 7 years.
  • Visual acuity, measured in each eye without cycloplegia in current refractive correction (if applicable) using the ATS-HOTV VA protocol on a study-approved device displaying single surrounded optotypes, as follows:
  • VA in the amblyopic eye 20/40 to 20/200 inclusive.
  • Age-normal VA in the fellow eye:44,45 • 4 years: 20/40 or better; 5-6 years: 20/32 or better; 7 years: 20/25 or better
  • Interocular difference ≥ 3 logMAR lines (i.e., amblyopic eye VA at least 3 logMAR lines worse than fellow eye VA).
  • Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated).
  • Criteria for strabismic amblyopia: At least one of the following must be met:
  • Presence of a heterotropia on examination at distance or near fixation (with optical correction), must be \<=5 prism diopters (∆) by SPCT at distance and near fixation (see #7 below).
  • Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia).
  • Criteria for anisometropia: At least one of the following criteria must be met:
  • ≥1.00 D difference between eyes in spherical equivalent (SE).
  • ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes.
  • Criteria for combined-mechanism: Both of the following criteria must be met:
  • A criterion for strabismus is met (see above).
  • ≥1.00 D difference between eyes in spherical equivalent OR ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes.
  • No more than 2 weeks (cumulative) of prior dichoptic treatment.
  • No treatment with cycloplegic eyedrops (e.g., atropine) in the past 2 weeks; other treatments allowed up to enrollment but then must be discontinued.
  • Refractive correction is required (single vision lenses or contact lenses) for any of the following refractive errors based on a cycloplegic refraction completed within the last 7 months:
  • Hypermetropia of 2.50 D or more by SE
  • Myopia of amblyopic eye of 0.50D or more SE
  • Astigmatism of 1.00D or more
  • Anisometropia of more than 0.50D SE NOTE: Monocular or binocular contact lens wear is allowed provided the contact lenses meet the refractive error correction requirements below. For each child, all testing must be performed using the same form of optical correction (i.e., no changing between contacts and spectacles).
  • Spectacles/contact lens correction prescribing instructions referenced to the cycloplegic refraction completed within the last 7 months:
  • SE must be within 0.50D of fully correcting the anisometropia (if new glasses are prescribed, reduction in plus sphere must be symmetric in the two eyes).
  • SE must not be under corrected by more than 1.50D SE.
  • Cylinder power in both eyes must be within 0.50D of fully correcting the astigmatism.
  • Axis must be within +/- 10 degrees if cylinder power is ≤1.00D, and within +/- 5 degrees if cylinder power is \>1.00D.
  • Myopia must not be under corrected by more than 0.25D or over corrected by more than 0.50D SE, and any change must be symmetrical in the two eyes.
  • Spectacles/contact lens correction (with or without other treatment such as patching) meeting the above criteria must be worn:
  • For at least 18 weeks OR until VA stability is documented (defined as \<0.1 logMAR change by the same testing method measured on 2 consecutive exams at least 9 weeks apart).
  • For determining VA stability (non-improvement):
  • The first of two measurements may be made 1) in current correction, or 2) in trial frames with or without cycloplegia or 3) without correction (if new correction is prescribed),
  • The second measurement must be made without cycloplegia in the correct spectacles/contact lens correction that has been worn for at least 9 weeks.
  • NOTE: Because this determination is a pre-randomization, the method of measuring VA is not mandated.
  • Participant is willing to wear the Luminopia headset.
  • Participant is willing to continue full-time spectacles/contact lens wear (if needed).
  • Participant is willing to accept assignment to either dichoptic shows (view 1 hour per day 6 days per week) OR part-time patching (2 hours per day 7 days per week) for 26 weeks.
  • Interpupillary distance of 52mm to 72mm inclusive.
  • Investigator is willing to prescribe Luminopia or patching per protocol.
  • Parent understands the protocol and is willing to accept randomization.
  • Parent has phone (or access to phone) and is willing to be contacted by JAEB Center.
  • Relocation outside area of active PEDIG site within the next 52 weeks is not anticipated. Individuals meeting any of the following criteria will be excluded from study participation.
  • Heterotropia more than 5∆ at distance or near (measured by SPCT in current correction)
  • Prism lenses or need of a prism prescription at enrollment.
  • Current bifocal spectacles (eligible only if bifocal discontinued 2 weeks prior to enrollment).
  • Myopia greater than -6.00D spherical equivalent in either eye.
  • Previous intraocular or refractive surgery.
  • Known skin reactions to patch or bandage adhesives.
  • Ocular co-morbidity that may reduce VA determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above visual acuity criteria are met using patch occlusion. Fogging is not permitted).
  • Diplopia more than once per week over the last week prior to enrollment by parental report.
  • History of light-induced seizures.
  • Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities are not excluded.
  • Participation in a prior study involving patching for amblyopia
  • Immediate family member (biological or legal guardian, child, sibling, parent) of investigative site personnel directly affiliated with this study or an employee of the JAEB center for Health Research.

Where

  • Birmingham, Alabama
  • Glendale, Arizona
  • Scottsdale, Arizona
  • Tucson, Arizona
  • Little Rock, Arkansas
  • Berkeley, California
  • Fullerton, California
  • Irvine, California
  • Los Angeles, California
  • Palo Alto, California
  • Pomona, California
  • Sacramento, California

And 49 more locations — see the full list below.

Collaborators

National Eye Institute (NEI), Pediatric Eye Disease Investigator Group

Related conditions & keywords

AmblyopiaDichopticLuminopiaPatchingmovie

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Feb 11, 2026 · Source of record for eligibility and locations

📊
1 of 238 participants interested
0% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Birmingham

Alabama

Location available
RECRUITING

Glendale

Arizona

Location available
RECRUITING

Scottsdale

Arizona

Location available
RECRUITING

Tucson

Arizona

Location available
RECRUITING

Little Rock

Arkansas

Location available
RECRUITING

Little Rock

Arkansas

Location available
RECRUITING

Berkeley

California

Location available
RECRUITING

Fullerton

California

Location available
RECRUITING

Irvine

California

Location available

And 64 more locations available.

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Looking for Amblyopia Treatment in Birmingham?

Join others in Alabama exploring innovative treatment options through clinical research

Amblyopia Treatment Options in Birmingham, Alabama

If you're searching for Amblyopia treatment in Birmingham, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Birmingham, Glendale, Scottsdale and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Amblyopia. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Alabama
Now Enrolling
Up to 238 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Amblyopia?

Potential Benefits

  • ✓Access to new treatment approaches before public availability
  • ✓Close monitoring by experienced medical professionals
  • ✓Study-related care provided at no cost
  • ✓Contribute to medical research for Amblyopia

What to Expect

  • →Initial screening to determine eligibility
  • →Regular check-ups and monitoring visits
  • →Possible compensation for time and travel
  • →You can withdraw at any time

Frequently Asked Questions About This Amblyopia Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06380517. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.